Nicole Y Fatheree1, Yuying Liu1, Christopher M Taylor2, Thomas K Hoang1, Chunyan Cai3, Mohammad H Rahbar4, Manouchehr Hessabi5, Michael Ferris2, Valarie McMurtry2, Christine Wong6, Ta Vu6, Theresa Dancsak7, Ting Wang1, Wallace Gleason1, Vinay Bandla1, Fernando Navarro1, Dat Q Tran1, J Marc Rhoads8. 1. Department of Pediatrics, the University of Texas Health Science Center at Houston McGovern Medical School, Houston, TX. 2. Department of Microbiology, Immunology & Parasitology Louisiana State University Health Sciences Center, New Orleans, LA. 3. Division of Clinical and Translational Sciences, Department of Internal Medicine, the University of Texas Health Science Center at Houston McGovern Medical School, Houston, TX; Biostatistics/Epidemiology/Research Design (BERD) Component, Center for Clinical and Translational Sciences (CCTS), the University of Texas Health Science Center at Houston, Houston, TX. 4. Division of Clinical and Translational Sciences, Department of Internal Medicine, the University of Texas Health Science Center at Houston McGovern Medical School, Houston, TX; Biostatistics/Epidemiology/Research Design (BERD) Component, Center for Clinical and Translational Sciences (CCTS), the University of Texas Health Science Center at Houston, Houston, TX; Division of Epidemiology, Human Genetics, and Environmental Sciences (EHGES), University of Texas School of Public Health at Houston, TX. 5. Biostatistics/Epidemiology/Research Design (BERD) Component, Center for Clinical and Translational Sciences (CCTS), the University of Texas Health Science Center at Houston, Houston, TX. 6. Memorial Hermann Hospital Investigational Drug Services, Memorial Hermann Hospital, Houston, TX. 7. Clinical Research Center, Memorial Hermann Hospital, Houston, TX. 8. Department of Pediatrics, the University of Texas Health Science Center at Houston McGovern Medical School, Houston, TX. Electronic address: J.Marc.Rhoads@uth.tmc.edu.
Abstract
OBJECTIVE: To assess the safety of probiotic Lactobacillus reuteri strain Deutsche Sammlung von Mikroorganismen (DSM) 17938 with daily administration to healthy infants with colic and to determine the effect of L reuteri strain DSM 17938 on crying, fussing, inflammatory, immune, and microbiome variables. STUDY DESIGN: We performed a controlled, double-blinded, phase 1 safety and tolerability trial in healthy breast-fed infants with colic, aged 3 weeks to 3 months, randomly assigned to L reuteri strain DSM 17938 (5 × 108 colony-forming units daily) or placebo for 42 days and followed for 134 days. RESULTS: Of 117 screened infants, 20 were randomized toL reuteri strain DSM 17938 or placebo (sunflower oil) (in a 2:1 ratio) with 80% retention. Eleven of the 20 (55%) presented with low absolute neutrophil counts (<1500/mm3), which resolved in all subjects by day 176. L reuteri strain DSM 17938 produced no severe adverse events and did not significantly change crying time, plasma bicarbonate, or inflammatory biomarkers. Fecal calprotectin decreased rapidly in both groups. In the infants with dominant fecal gram negatives (Klebsiella, Proteus, and Veillonella), resolution of colic was associated with marked decreases in these organisms. CONCLUSIONS: Daily administration of L reuteri strain DSM 17938 appears to be safe in newborn infants with colic, including those with neutropenia, which frequently coexists. A placebo response of 66% suggests that many infants with colic will have resolution within 3 weeks. TRIAL REGISTRATION: ClinicalTrials.gov: NCT01849991.
RCT Entities:
OBJECTIVE: To assess the safety of probiotic Lactobacillus reuteri strain Deutsche Sammlung von Mikroorganismen (DSM) 17938 with daily administration to healthy infants with colic and to determine the effect of L reuteri strain DSM 17938 on crying, fussing, inflammatory, immune, and microbiome variables. STUDY DESIGN: We performed a controlled, double-blinded, phase 1 safety and tolerability trial in healthy breast-fed infants with colic, aged 3 weeks to 3 months, randomly assigned to L reuteri strain DSM 17938 (5 × 108 colony-forming units daily) or placebo for 42 days and followed for 134 days. RESULTS: Of 117 screened infants, 20 were randomized to L reuteri strain DSM 17938 or placebo (sunflower oil) (in a 2:1 ratio) with 80% retention. Eleven of the 20 (55%) presented with low absolute neutrophil counts (<1500/mm3), which resolved in all subjects by day 176. L reuteri strain DSM 17938 produced no severe adverse events and did not significantly change crying time, plasma bicarbonate, or inflammatory biomarkers. Fecal calprotectin decreased rapidly in both groups. In the infants with dominant fecal gram negatives (Klebsiella, Proteus, and Veillonella), resolution of colic was associated with marked decreases in these organisms. CONCLUSIONS: Daily administration of L reuteri strain DSM 17938 appears to be safe in newborn infants with colic, including those with neutropenia, which frequently coexists. A placebo response of 66% suggests that many infants with colic will have resolution within 3 weeks. TRIAL REGISTRATION: ClinicalTrials.gov: NCT01849991.
Authors: Margaret N Kosek; Pablo Peñataro-Yori; Maribel Paredes-Olortegui; John Lefante; Cesar Ramal-Asayag; Marcelo Zamora-Babilonia; Graciela Meza-Sanchez; Richard A Oberhelman Journal: Pediatr Infect Dis J Date: 2019-08 Impact factor: 2.129
Authors: Julie D Thai; Sara Cherkerzian; Evgenia J Filatava; Ngan Luu; Hidemi S Yamamoto; Raina N Fichorova; Mandy B Belfort; Katherine E Gregory Journal: J Pediatr Gastroenterol Nutr Date: 2022-04-26 Impact factor: 3.288
Authors: Tu Mai; Nicole Y Fatheree; Wallace Gleason; Yuying Liu; Jon Marc Rhoads Journal: Gastroenterol Clin North Am Date: 2018-09-28 Impact factor: 3.806
Authors: Melinda A Engevik; Christina N Morra; Daniel Röth; Kristen Engevik; Jennifer K Spinler; Sridevi Devaraj; Sue E Crawford; Mary K Estes; Markus Kalkum; James Versalovic Journal: Front Microbiol Date: 2019-10-09 Impact factor: 5.640